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THE mechanism for the initiation of blood-brain barrier
damage and intrathecal inflammation in patients infected
with the human immunodeficiency virus (HIV) is poorly
understood. We have recently reported that tumour necro-
sis factor-e (TNF-e) mediates active neural inflammation
and blood-brain barrier damage in HIV-1 infection. Sti-
mulation of endothelial cells by TNF-e induces the ex-
pression of intercellular adhesion molecule-1 (ICAM-1),
which is an important early marker of immune activation
and response. We report herein for the first time the
detection of high levels of free circulating ICAM-1 in
serum and cerebrospinal fluid of patients with HIV-1
infection. Free circulating ICAM-1 in these patients corre-
lated with TNF-e concentrations and with the degree of
blood-brain barrier damage and were detected predom-
inantly in patients with neurologic involvement. These
findings have important implications for the understand-
ing and investigation of the intrathecal inflammatory re-
sponse in HIV-1 infection.
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Introduction
Neurologic involvement is a frequent feature of
human immunodeficiency virus (HIV) infection
and may be the initial presentation in about 10% of
patients.
2 There is increasing evidence that indirect
mechanisms, such as the release of cytokines, play
an important role in mediating brain inflammation
in HIV infection. Indeed it is now widely
acknowledged that tumour necrosis factor-
(TNF-z), a central mediator of inflammation, plays
a crucial role in the development of acquired
immunodeficiency syndrome (AIDS).
3 TNF-z is
implicated in the pathogenesis of most clinical and
pathologic features of AIDS3 and selectively kills
HIV-infected cells, probably through a direct
cytotoxic effect. Furthermore, TNF- enhances the
replication of HIV and induces the expression of a
wide array of inflammatory cytokines.
Damage to cerebral endothelial cells and
blood-brain barriers is another important patho-
logic feature that contributes to brain damage in
HIV infection. Neuropathologic studies have
clearly demonstrated that cerebral vasculitis is an
early and frequent pathologic feature in HIV
seropositive subjects.
4 Such vascular inflammation
seems to be immune mediated4’s and could be
connected to the release of inflammatory mediators.
Evidence has been presented that TNF-z induces
inflammatory changes on human cerebral en-
dothelial cells. 6’7 Moreover, we have recently shown
in a different series of patients that TNF-o mediates
blood-brain barrier damage in HIV infected
patients.
8 However, the precise mechanism of the
TNF<z mediated endothelial damage and the
mechanism by which circulating immune cells
recognize the HIV infected cells, including cerebral
endothelium, are not well understood.
Adhesion of inflammatory cells to vascular
endothelium is essential for. their migration into
inflamed tissues. Endothelial cells lining the
postcapillary venules and microcirculation elaborate
several adhesion molecules both constitutively and
in response to a wide range of inflammatory
mediators.9’1 Detection of adhesion molecules
expression in vivo at sites of acute immunologic
inflammation
1 has been used to infer that functional
activation of the endothelium may be occurring at
these sites.
Intracellular adhesion molecule-1 (1CAM-l,
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CD54), a molecule bound to the ceil surface
membrane, is an important early marker of immune
activation and response12’13 including the produc-
tion of inflammatory vascular injury in io. TM
Although the expression of ICAM-1, which may
confer adhesivity for lymphocytes is most common
in haematopoietic tissues, it is also detected in
several organs, including the central nervous system
(CNS).
1 The presence of free circulating ICAM-1
(clCAM-1) has been recently documented in human
sera16’17 and the expression of ICAM-1 is
upregulated by TNF- and other cytokines.
18 There
is also increasing evidence that adhesion receptors
can play a significant role in the pathogenesis of
AIDS (reviewed by Koopman and Palsl9).
In this study, serum and CSF samples from HIV
infected patients have been examined for the
presence of free clCAM-1, as an in vivo marker of
endothelial cell activation. It is believed this is the
first time that circulating ICAM-1 has been shown
to be present in serum and CSF from HIV infected
patients and that it correlates with both TNF-
levels and the degree ofblood-brain barrier damage.
Patients and Methods
Patients: Paired CSF and serum samples were
obtained from 37 HIV type-1 (HIV-1) seropositive
patients (28 males, 9 females; median age 27.6 years,
age range 19-49 years). Patients were classified
according to the guidelines of the Centres for
Disease control
2 and their clinical features are
presented in Table 1.
Cerebrospinal fluid was obtained by a lumbar
puncture and cells were separated by cyto-
centrifugation then all samples were filtered
through a 0.45 #m disposable sterile filter
(Millipore, Harrow, UK) to remove contaminating
particulate materials. The CSF was concentrated by
means of Minicon CS15 concentrators (Amicon,
Upper Mill, UK). Samples were frozen in aliquots at
--70C and thawed just before use; repeated
Table 1. CDC classification of 37 HIV-1 seropositive patients
included in the study
No. of Clinical features
patients
Group II 2
Group III 4
Group IV
Subgroup A 5
Subgroup B 8
Subgroup C
Category C- 6
Category C-2 9
Subgroup D 3
Asymptomatic HIV-1 infection
Persistent generalized
lymphadenopathy
Constitutional disease
Neurological disease
Specified secondary infections
within the CNS
Other specified secondary infections
Secondary cancers
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thawing and refreezing was avoided. Neurosyphilis,
frequently associated with HIV infection, was
excluded in all patients by fluorescent treponemal
antibody absorption and treponemal haemoaggluti-
nation tests.
Controls: Control CSF and serum samples were
obtained from 30 HIV-1 seronegative patients with
various non-inflammatory neurologic diseases in
whom signs of blood-brain barrier damage were
detected at presentation. They included eight
patients with meningioma, four with craniophar-
yngioma, five with intracranial arteriovenous
malformation, six with cerebrovascular diseases,
three with benign intracranial hypertension, and
four with obstructive hydrocephalus. Paired sam-
ples were also obtained from 18 normal subjects
(median age 32.5 years, range 16-54 years) to
determine reference ranges. These subjects pre-
sented with nonspecific complaints such as
headache or blurring of vision and neurologic
examination as well as detailed investigations had
excluded a specific cause of their symptoms.
Detection of cICAM-I: Measurement of circulating
immunoreactive ICAM-1 in serum and CSF samples
was performed by a sensitive dot blot analysis
16 with
minor modifications. In brief, 1:50 diluted serum
and CSF samples concentrated to the same albumin
level were spotted onto polyvinyl difluoride
membrane (Immobilon, Millipore, Harrow). After
nonspecific blocking and washing, the blots
were incubated with a monoclonal antibody to
ICAM-121 and subsequently incubated with a
peroxidase-conjugated F(ab’)2 fragment (Sigma, St
Louis, MO, USA). The blots were then developed
with a chromogen solution containing 0-phenylene-
diamine dihydrochloride and 100#1 H202 in
100 ml of 0.02 M acetate buffer. As controls, blots
were incubated without the first antibody and with
a Mab (anti-CD18) against the common beta chain
of LFA-1 and Mac-1.
Quantitative analysis of the blots was performed
by densitometric evaluation as recently described=
using a Joyce Loebl Chromoscan 3 densitometric
scanner. The intensity of the colour reaction of
blots is dependent on the ICAM-1 concentration in
the test samples. The colour intensity was measured
as reflected light and the maximum absorption was
determined at 492 nm. The lower limit of the
detection of clCAM-1 is 8 ng/ml.
Other assays: Levels of TNF-0 in the test samples
were determined by a sandwich-type enzyme-linked
immunoassay (ELISA) described previously.
23 A
standard curve was run on each ELISA plate using
recombinant human TNF- in serial dilutions.
Albumin concentrations in CSF and serum samples
were measured by electroimmunoassay. The in-ICAM-1 and TNF- in HIV-1 infection
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FIG. 1. Dot blots showing the presence of clCAM-1 in serum and CSF;
each sample was analysed in duplicate. Lanes to 7 samples from
patients with HIV-1 infection; lane 8 samples from a healthy subject;
and lane 9 blots incubated with monoclonal antibodies against CD18
to serve as control.
tegrity of the blood-brain barrier was assessed by
calculating CSF to serum albumin quotient (Qalb)
24
and the degree of barrier damage was graduated
according to Qalb as already described, as
Results
Distribution of cICAM- A variable range of
intensities of free clCAM-1 was detected in serum
from the control healthy individuals (Figure 1);
however, no cICAM-1 reactivity was seen in their
CSF. The mean 4-2 SD of maximum absorbance
of clCAM-1 in serum from healthy controls
(19.7 + 14.6%) was calculated as the cut-off value
for determining abnormally high amounts of
clCAM-1 in the study population.
High clCAM-1 levels (above the cut-off value
in normal controls) were detected in serum of 25
HIV-1 seropositive patients and 13 seronegative
controls, whereas cICAM-1 in CSF was seen
predominantly in HIV-1 serpositive pttients
(Table 2). Serum cICAM-1 in HIV-1 seropositive
patients correlated with corresponding CSF
amounts (r 0.61, p < 0.001). Free clCAM-1
was detected in CSF of all HIV-1 seropositive
patients with neurologic involvement but was not
detected in CDC groups II or Ili; however,
cICAM-1 was also detected in CSF of group
IV-A patients who showed no clinical evidence of
neurologic disease.
Correlation of cICAM-I with TNF- levels: As shown
in Table 2, high TNF-0 levels were seen in serum
of 20 and in CSF of 22 HIV-1 seropositive patients.
There was a strong association between TNF-0 and
clCAM-1 in the test samples. Of the 22 seropositive
patients who had high CSF TNF- levels, 17 (77%)
had high CSF cICAM-1 levels, whereas only two
(13%) of 15 patients with no detectable TNF- in
CSF had high CSF cICAM-1 levels. Similarly, 18
(90%) of the 20 patients with high serum levels of
TNF-0 had high levels of serum clCAM-1, and only
two (10%) patients with high serum TNF-0 levels
had normal serum clCAM-1 levels.
The 20 seropositive patients with high serum
TNF-0 had higher levels of cICAM-1 in serum
(mean absorbance SD 69.5 4- 20.9%) com-
pared to those who had no detectable serum TNF-a
(mean absorbance 36.1 4- 18.8%, p < 0.01).
Similarly, CSF levels of cICAM-1 (mean absor-
bance 54.2 4- 30.2%) in HIV-1 seropositive
patients who had high CSF TNF-0 were signifi-
cantly higher than CSF clCAM-1 in patients with
no detectable TNF-0 in CSF (mean absor-
bance 22.9 _4- 20.8%,p < 0.001). Moreover, indi-
vidual levels of TNF-a in HIV-1 seropositive
patients significantly correlated with cICAM-1 in
both serum and CSF (Figure 2).
No correlation between TNF- and cICAM-1
was observed in the HIV-1 seronegative controls.
High TNF-0 levels were detected in CSF of three
seronegative controls who had no clCAM-1 in CSF
and six of the 13 seronegative controls with high
serum cICAM-1 levels had no measurable serum
TNF-a levels. Furthermore, mean absorbance of
serum cICAM-1 (48.4 _4- 12.7%) and CSF (17.3 4-
11.4%) in seronegative controls with detectable
TNF-0 levels were not significantly different from
those with no measurable TNF-0 (mean absor-
bance 31.2 4- 14.1% and 13.2 4- 12.6% respec-
tively).
Correlation of dCAM-1 with blood-brain barrier damage:
Twenty-four HIV-1 seropositive patients had high
Qalb values suggestive of blood-brain barrier
damage. All HIV-1 seropositive patients who had
Table 2. Distribution of clCAM-1 and TNF- levels in 37 HIV-1 seropositive patients and 30 seronegative controls
showing those with abnormally high values
Variable H IV-1 seropositive patients H IV-1 seronegative controls
Median (abnormal) Range Median (abnormal) Range
Serum clCAM- (% absorbance)
CSF clCAM-1 (% absorbance)
Serum TNF- (unit/ml)
CSF TNF- (unit/ml)
53.2 (25) 6-97 38.1 (13) 4-73
42.7 (19) 0-98 9.4 (5) 0-53
54.8 (20) 4.5-175 40.2 (8) 2-123
47.3 (22) 0-163 31.8 (5) 0-87
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100
80
6o
40
0 50 I00 150 200
Serum TNF-a (Unit/ml)
100
< 60
D 40
20
0.73, p < 0.001
0 @
0 -5 100 150 200
I00
80
60
40
20
0.69, sip < 0.001
0
0 5 I0 15 20 25
Albumin quotient x 1000)
FIG. 3. Correlation of CSF clCAM-1 with CSF to serum albumin quotient
in HIV-1 seropositive patients. Those with undetectable clCAM-1 in CSF
are not included.
damage (corrected 2 6.8, p < 0.05). Moreover,
levels of cICAM-1 in serum and CSF of HIV-1
seropositive patients correlated with the degree of
barrier damage (Figure 4). In contrast, the degree
of blood-brain barrier damage in seronegative
controls did not correlate with either serum or CSF
levels of cICAM-1.
Discussion
In this study of HIV-1 seropositive patients who
have relatively high levels ofclCAM-1 in serum and
CSF, a correlation with both serum and CSF TNF-
levels and the degree of blood-brain barrier damage
was observed. It is thought that this represents the
CSF TNF-a (Unit/ml)
FIG. 2. (a) Correlation of clCAM-1 with TNF- levels in the serum of
HIV-1 seropositive patients. Patients with both normal levels of clCAM-1
and absent TNF-= are not shown. (b) Correlation of clCAM-1 with TNF-
levels in the CSF of HIV-1 seropositive patients. Patients with no
measurable clCAM-1 and TNF-a in CSF are not shown.
abnormally high CSF cICAM-1 demonstrated high
Qalb values (mean Qalb 10.8 + 3.7) indicative of
blood-brain barrier damage (Figure 3), whereas
only five patients (28%) with no detectable
cICAM-1 in CSF showed evidence of barrier
damage (mean Qalb 6.1 _--t- 2.8, p < 0.01). Simi-
larly, high levels of cICAM-1 in serum of HIV-1
seropositive patients were associated with sig-
nificantly higher incidence of blood-brain barrier
IC,
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FIG. 4. Correlation ot CSF and serum clCAM-1 reactivity with the
degree of blood-brain barrier damage in 37 HIV-1 seropositive patients.
326 Mediators of Inflammation. Vol 1992ICAM-1 and TNF- in HIV-1 infection
first demonstration of a free circulating endothelial
cell-leucocyte adhesion molecule in HIV-1 infec-
tion. The detection of cICAM-1 raises the question
of whether circulating levels of this molecule reflect
the amount of ICAM-1 that is bound to the cell
surface membrane and pathologic studies are clearly
required to evaluate the importance of cICAM-1 in
HIV-1 infection.
The presence of high levels of free circulating
ICAM-1 in patients with HIV-1 infections also
raises the question of whether this molecule carries
out biological functions similar to its cell surface
bound counterpart, such as the regulation of the
intercellular adhesion process. Recent evidence17
suggests that cICAM-1 retains almost all extra-
cellular domains of membrane ICAM-1 and most
structural features necessary for binding to the
adhesion receptor lymphocyte function associated
antigen 1. Thus, further characterization of
cICAM-1 may provide insight into the pathophy-
siology of inflammatory CNS involvement during
HIV-1 infection, particularly the impairment of the
blood-brain barrier.
The blood-brain barrier, which is formed by
specialized endothelial cells, regulates the interac-
tion between the immune and the central nervous
systems. In the normal brain there is very limited
lymphocyte traffic, but lymphocyte infiltration is
critical for the pathogenesis of several brain
diseases.26’27 A crucial early step in mounting an
effective inflammatory or immune response is the
promotion of leucocyte adhesion to the vascular
endothelium before they can migrate chemotactic-
ally to the appropriate microenvironment.9 1CAM-1
is highly inducible on various cell types, particularly
endothelial cells, during inflammation and in
response to proinflammatory cytokines, which
suggests that 1CAM-1 upregulation and cell surface
expression are important in the regulation of
28 immune responses.
It has been reported recently that the expression
of 1CAM-1 is important in leucocyte homing and
adhesion to the blood-brain barrier during active
stages of experimental autoimmune demyelina-
tion.
29 Similarly, the expression of adhesion
molecules at the blood-brain barrier has been
demonstrated recently in humans.3’3. Since neuro-
logic involvement in HIV-1 infection is commonly
associated with cerebral endothelial and blood-brain
barrier damage,
32-34 which can be mediated by
TNF-a,
8 it is reasonable to suggest that 1CAM-1
may act as a homing signal in HIV-1 related CNS
inflammation. In addition, the adhesive interactions
between inflammatory cells and the functional
adhesion molecules expressed on endothelial cells
may result in the activation of inflammatory cells
prior to their migration into the intrathecal
compartment. The lack of correlation between
clCAM-1 and non-inflammatory blood-brain bar-
rier damage observed in the seronegative controls
further underlies the potential importance of
1CAM-1 in the regulation of CNS inflammation.
Whether the release of cICAM-1 preceded or
occurred during damage to the blood-brain barrier
is not yet clear but will be the subject of further
studies.
Free cICAM-1 was detected in CSF of all HIV-1
seropositive patients with neurologic involvement
but was absent from CSF of patients with early
HIV-1 infection (i.e. CDC groups II and III) who
had no evidence of neurologic disease. In this
regard, cICAM-1 could be a useful marker of
neurologic involvement in patients with HIV-1
infection. The presence of clCAM-1 in CSF of
patients with constitutional disease (CDC group
IV-A), however, suggests that the intrathecal
release of this molecule may precede the onset of
clinically manifested neurologic disease.
The correlation between cICAM-1 and levels of
TNF- presented here extends earlier in vitro
observations, which reported an increased expres-
sion of 1CAM-1 on brain microvascular endothelial
cells after activation of the cell with TNF- or other
proinflammatory cytokines in a dose-dependent
manner.
3s Further evidence was presented recently
that the TNF- mediated increase in vascular
permeability and oedema are instituted by 1CAM-I-
dependent mechanisms36--a fact that may explain
the significant correlation of cICAM-1 with both
TNF- levels and blood-brain barrier damage in our
patients.
The importance of our results is also suggested
by recent in vivo studies, which detected abundant
expression of ICAM-1 on brain endothelial cells in
inflammatory/infectious CNS diseases, such as
herpes simplex encephalitis and in active multiple
sclerosis plaques.
5 Interestingly, ICAM-1 is poorly
expressed by CNS endothelial cells in animals
without an intrathecal inflammatory process,
37 but
ICAM-1 expression is upregulated during the initial
phase of chronic relapsing allergic encephalomyeli-
tis in association with inflammatory cell invasion.
9
In conclusion, these results suggest that cICAM-
1 may be important in the pathogenesis of
inflammatory changes within the intrathecal com-
partment of HIV-1 infected patients. The correla-
tion of cICAM-1 with both TNF- concentrations
and the degree of blood-brain barrier damage
supports a functional role. It has to be noted,
however, that the molecular events regulating
cellular migration to the intrathecal compartment
are multifactorial and involve several adhesion
molecules in addition to ICAM-1. Analysing the
dynamics of these molecules is crucial to evaluate
the inflammatory cell invasion of CNS in HIV-1
infection.
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